Trials / Withdrawn
WithdrawnNCT04127695
A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease
A Randomized, Double-Blind, Placebo Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of ABBV-0805 in Patients With Parkinson's Disease
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 85 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and tolerability of ABBV-0805 in adult participants with Parkinson's Disease and results from it will help guide the design of future clinical studies. ABBV-0805 is administered every 28 days by intravenous (IV) infusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABBV-0805 | ABBV-0805 administered by IV infusion. |
| DRUG | Placebo ABBV-0805 | Placebo ABBV-0805 administered by IV infusion. |
Timeline
- Start date
- 2020-03-03
- Primary completion
- 2020-06-16
- Completion
- 2020-06-16
- First posted
- 2019-10-15
- Last updated
- 2021-12-15
Locations
6 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04127695. Inclusion in this directory is not an endorsement.